NCT00401024 2018-06-28
Tumor Tissue Analysis in Patients Receiving Imatinib Mesylate for Malignant Glioma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Completed
Clinical Trials
8 trialsNCT00010049 2018-06-27
Imatinib Mesylate in Treating Patients With Recurrent Malignant Glioma or Meningioma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1/2 Completed
NCT00387933 2015-10-14
Imatinib Mesylate, Vatalanib, and Hydroxyurea in Treating Patients With Recurrent or Relapsed Malignant Glioma
Duke University
Phase 1 Completed
NCT00354068 2013-03-28
Imatinib Mesylate and Temozolomide in Treating Patients With Malignant Glioma
Duke University
Phase 1 Completed
NCT00615927 2013-03-15
Phase II Imatinib + Hydroxyurea in Treatment of Patients With Recurrent/Progressive Grade II Low-Grade Glioma (LGG)
Duke University
Phase 2 Completed
NCT00613132 2013-02-20
Ph I Gleevec in Combo w RAD001 + Hydroxyurea for Pts w Recurrent MG
Duke University
Phase 1 Completed
NCT00354913 2013-01-18
Imatinib Mesylate and Hydroxyurea in Treating Patients With Recurrent or Progressive Meningioma
Duke University
Phase 2 Completed
NCT00613054 2012-12-05
Ph I Zactima + Imatinib Mesylate & Hydroxyurea for Pts w Recurrent Malignant Glioma
Duke University
Phase 1 Completed